FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385230296> ?p ?o ?g. }

• W4385230296 endingPage "e2325415" @default.
• W4385230296 startingPage "e2325415" @default.
• W4385230296 abstract "Importance Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent that has shown promising findings in a phase 2 clinical trial in patients with acute ischemic stroke (AIS). Objective To evaluate the efficacy and safety of rhPro-UK thrombolysis within 4.5 hours of symptom onset in patients with AIS. Design, Setting, and Participants This randomized, alteplase-controlled, open-label, phase 3 clinical trial was conducted from May 2018 to May 2020 at 35 medical centers in China. A total of 684 patients were screened and 674 patients were enrolled. Included patients were aged 18 to 80 years with a diagnosis of AIS and received treatment within 4.5 hours of stroke onset. Data were analyzed from June to October 2020. Interventions Eligible patients were randomly assigned (1:1) to receive intravenous rhPro-UK or alteplase. Main Outcomes and Measures The primary objective was to assess whether rhPro-UK was noninferior to alteplase. The noninferiority margin was a between-group difference of less than 10%. The primary outcome was a modified Rankin Scale score of 0 to 1 at 90 days. Results Among 663 patients in the modified intention-to-treat population (mean [SD] age, 61.00 [10.20] years; 161 females [24.3%]), there were 330 patients in the rhPro-UK group and 333 patients in the alteplase group. The median (IQR) baseline National Institutes of Health Stroke Scale score was 6.00 (5.00-9.00). There were 23 deaths, and 619 patients (93.4%) completed the 3-month follow-up. The primary outcome occurred in 215 patients (65.2%) in the rhPro-UK group and 214 patients (64.3%) in the alteplase group (risk difference, 0.89; 95.4% CI, −6.52 to 8.29). Symptomatic intracerebral hemorrhage occurred in 5 patients (1.5%) in the rhPro-UK group and 6 patients (1.8%) in the alteplase group ( P &amp;gt; .99). Systemic bleeding within 90 days occurred more frequently in the alteplase group (141 patients [42.2%]) than the rhPro-UK group (85 patients [25.8%]) ( P &amp;lt; .001). By 90 days, 5 thrombolysis-related deaths each had occurred in the rhPro-UK group (1.5%) and alteplase group (1.5%) ( P &amp;gt; .99). Conclusions and Relevance This study found that intravenous rhPro-UK within 4.5 hours of AIS onset was noninferior to alteplase. The rhPro-UK group showed a similar rate of symptomatic ICH but fewer cases of systemic bleeding than the alteplase group. Trial Registration ClinicalTrials.gov Identifier: NCT03541668" @default.
• W4385230296 created "2023-07-26" @default.
• W4385230296 creator A5004517213 @default.
• W4385230296 creator A5006015401 @default.
• W4385230296 creator A5007727230 @default.
• W4385230296 creator A5013015632 @default.
• W4385230296 creator A5013938837 @default.
• W4385230296 creator A5015317090 @default.
• W4385230296 creator A5017774638 @default.
• W4385230296 creator A5018211821 @default.
• W4385230296 creator A5021212748 @default.
• W4385230296 creator A5024202469 @default.
• W4385230296 creator A5024282499 @default.
• W4385230296 creator A5024643453 @default.
• W4385230296 creator A5025592561 @default.
• W4385230296 creator A5026338064 @default.
• W4385230296 creator A5028708493 @default.
• W4385230296 creator A5030968272 @default.
• W4385230296 creator A5032686951 @default.
• W4385230296 creator A5032730345 @default.
• W4385230296 creator A5038264942 @default.
• W4385230296 creator A5038730375 @default.
• W4385230296 creator A5042613850 @default.
• W4385230296 creator A5043945941 @default.
• W4385230296 creator A5044847127 @default.
• W4385230296 creator A5045117407 @default.
• W4385230296 creator A5052058659 @default.
• W4385230296 creator A5053974832 @default.
• W4385230296 creator A5055222319 @default.
• W4385230296 creator A5055367068 @default.
• W4385230296 creator A5055848435 @default.
• W4385230296 creator A5060121971 @default.
• W4385230296 creator A5060737477 @default.
• W4385230296 creator A5061550065 @default.
• W4385230296 creator A5061580592 @default.
• W4385230296 creator A5061705806 @default.
• W4385230296 creator A5062755510 @default.
• W4385230296 creator A5067301238 @default.
• W4385230296 creator A5067703908 @default.
• W4385230296 creator A5070578002 @default.
• W4385230296 creator A5071671188 @default.
• W4385230296 creator A5073121274 @default.
• W4385230296 creator A5077782269 @default.
• W4385230296 creator A5080176831 @default.
• W4385230296 creator A5081675173 @default.
• W4385230296 creator A5084704484 @default.
• W4385230296 creator A5085136795 @default.
• W4385230296 creator A5087644437 @default.
• W4385230296 creator A5088510694 @default.
• W4385230296 creator A5090815103 @default.
• W4385230296 creator A5091449910 @default.
• W4385230296 date "2023-07-25" @default.
• W4385230296 modified "2023-09-29" @default.
• W4385230296 title "Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset" @default.
• W4385230296 cites W1996802760 @default.
• W4385230296 cites W2004225408 @default.
• W4385230296 cites W2032364607 @default.
• W4385230296 cites W2052834936 @default.
• W4385230296 cites W2080932123 @default.
• W4385230296 cites W2102447759 @default.
• W4385230296 cites W2105699409 @default.
• W4385230296 cites W2132305654 @default.
• W4385230296 cites W2157595656 @default.
• W4385230296 cites W2159233098 @default.
• W4385230296 cites W2164763924 @default.
• W4385230296 cites W2171165037 @default.
• W4385230296 cites W2203834727 @default.
• W4385230296 cites W2292308933 @default.
• W4385230296 cites W2420502441 @default.
• W4385230296 cites W2740053016 @default.
• W4385230296 cites W2754229858 @default.
• W4385230296 cites W2766427227 @default.
• W4385230296 cites W2768386630 @default.
• W4385230296 cites W3032066383 @default.
• W4385230296 cites W3193313959 @default.
• W4385230296 cites W4213019574 @default.
• W4385230296 cites W4224311521 @default.
• W4385230296 cites W4225309632 @default.
• W4385230296 cites W4237707316 @default.
• W4385230296 cites W4255683973 @default.
• W4385230296 cites W4302435467 @default.
• W4385230296 doi "https://doi.org/10.1001/jamanetworkopen.2023.25415" @default.
• W4385230296 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37490291" @default.
• W4385230296 hasPublicationYear "2023" @default.
• W4385230296 type Work @default.
• W4385230296 citedByCount "1" @default.
• W4385230296 countsByYear W43852302962023 @default.
• W4385230296 crossrefType "journal-article" @default.
• W4385230296 hasAuthorship W4385230296A5004517213 @default.
• W4385230296 hasAuthorship W4385230296A5006015401 @default.
• W4385230296 hasAuthorship W4385230296A5007727230 @default.
• W4385230296 hasAuthorship W4385230296A5013015632 @default.
• W4385230296 hasAuthorship W4385230296A5013938837 @default.
• W4385230296 hasAuthorship W4385230296A5015317090 @default.
• W4385230296 hasAuthorship W4385230296A5017774638 @default.
• W4385230296 hasAuthorship W4385230296A5018211821 @default.
• W4385230296 hasAuthorship W4385230296A5021212748 @default.
• W4385230296 hasAuthorship W4385230296A5024202469 @default.

• next